Taltz-话题@MedSci

#Taltz#

8篇内容 | 658人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1674295, encodeId=d32416e429552, content=<a href='/topic/show?id=a5261e119fc' target=_blank style='color:#2F92EE;'>#Taltz#</a>, objectTitle=ARD:评估Taltz(ixekizumab)与阿达木单抗治疗银屑病关节炎患者的疗效和安全性, objectType=article, longId=216821, objectId=a6d72168217e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6d72168217e, replyNumber=0, likeNumber=43, createdTime=2021-11-06, rootId=0, userName=hjwang88, userId=3a9a26964526, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6d72168217e, moduleTitle=ARD:评估Taltz(ixekizumab)与阿达木单抗治疗银屑病关节炎患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6d72168217e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1674293, encodeId=05be16e4293c3, content=<a href='/topic/show?id=a5261e119fc' target=_blank style='color:#2F92EE;'>#Taltz#</a>, objectTitle=礼来的IL-17A单抗Taltz获得FDA批准扩展用于活动性强直性脊柱炎, objectType=article, longId=178241, objectId=2a911e824102, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a911e824102, replyNumber=0, likeNumber=43, createdTime=2020-04-14, rootId=0, userName=hjwang88, userId=3a9a26964526, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a911e824102, moduleTitle=礼来的IL-17A单抗Taltz获得FDA批准扩展用于活动性强直性脊柱炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a911e824102)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1674294, encodeId=f07016e4294dd, content=<a href='/topic/show?id=a5261e119fc' target=_blank style='color:#2F92EE;'>#Taltz#</a>, objectTitle=头对头牛皮癣研究中，礼来的IL-17A单抗Taltz与强生的IL-23单抗Tremfya相比可提高皮肤清除率, objectType=article, longId=180571, objectId=711e1805e121, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=711e1805e121, replyNumber=0, likeNumber=25, createdTime=2020-09-03, rootId=0, userName=hjwang88, userId=3a9a26964526, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=711e1805e121, moduleTitle=头对头牛皮癣研究中，礼来的IL-17A单抗Taltz与强生的IL-23单抗Tremfya相比可提高皮肤清除率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=711e1805e121)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1674292, encodeId=21c016e42921d, content=<a href='/topic/show?id=a5261e119fc' target=_blank style='color:#2F92EE;'>#Taltz#</a>, objectTitle=礼来的IL-17A单抗Taltz治疗非放射性轴向脊柱关节炎，III期临床试验大获成功, objectType=article, longId=164909, objectId=f4ff16490983, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4ff16490983, replyNumber=0, likeNumber=35, createdTime=2019-09-08, rootId=0, userName=hjwang88, userId=3a9a26964526, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4ff16490983, moduleTitle=礼来的IL-17A单抗Taltz治疗非放射性轴向脊柱关节炎，III期临床试验大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4ff16490983)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1674291, encodeId=a8e716e4291b6, content=<a href='/topic/show?id=a5261e119fc' target=_blank style='color:#2F92EE;'>#Taltz#</a>, objectTitle=Lilly将启动IXORA-R头对头试验：比较IL-17A单抗Taltz和IL-23单抗Tremfya治疗中度至重度斑块型银屑病患者的疗效, objectType=article, longId=148645, objectId=6dae148645a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6dae148645a9, replyNumber=0, likeNumber=32, createdTime=2018-11-21, rootId=0, userName=hjwang88, userId=3a9a26964526, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6dae148645a9, moduleTitle=Lilly将启动IXORA-R头对头试验：比较IL-17A单抗Taltz和IL-23单抗Tremfya治疗中度至重度斑块型银屑病患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6dae148645a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1674290, encodeId=ff1d16e42901c, content=<a href='/topic/show?id=a5261e119fc' target=_blank style='color:#2F92EE;'>#Taltz#</a>, objectTitle=礼来公司对银屑病关节炎的Taltz在欧盟获批, objectType=article, longId=127641, objectId=bc2312e64177, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc2312e64177, replyNumber=0, likeNumber=28, createdTime=2018-04-30, rootId=0, userName=hjwang88, userId=3a9a26964526, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc2312e64177, moduleTitle=礼来公司对银屑病关节炎的Taltz在欧盟获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc2312e64177)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1674289, encodeId=18a816e4289e2, content=<a href='/topic/show?id=a5261e119fc' target=_blank style='color:#2F92EE;'>#Taltz#</a>, objectTitle=LANCET：牛皮癣患者福音！新药Taltz赶走可怕的牛皮癣并发症, objectType=article, longId=100168, objectId=645610016850, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=645610016850, replyNumber=0, likeNumber=49, createdTime=2017-12-10, rootId=0, userName=hjwang88, userId=3a9a26964526, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=645610016850, moduleTitle=LANCET：牛皮癣患者福音！新药Taltz赶走可怕的牛皮癣并发症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=645610016850)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1674288, encodeId=95d616e4288aa, content=<a href='/topic/show?id=a5261e119fc' target=_blank style='color:#2F92EE;'>#Taltz#</a>, objectTitle=FDA批准银屑病治疗药Taltz, objectType=article, longId=65436, objectId=4ade6543605, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ade6543605, replyNumber=0, likeNumber=26, createdTime=2016-11-21, rootId=0, userName=hjwang88, userId=3a9a26964526, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ade6543605, moduleTitle=FDA批准银屑病治疗药Taltz, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ade6543605)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Taltz

2020-05-29

hjwang88 (审核中...)

前往app查看评论内容

#Taltz#

ARD:评估Taltz(ixekizumab)与阿达木单抗治疗银屑病关节炎患者的疗效和安全性

2021-11-06

hjwang88 (审核中...)

前往app查看评论内容

#Taltz#

礼来的IL-17A单抗Taltz获得FDA批准扩展用于活动性强直性脊柱炎

2020-04-14

hjwang88 (审核中...)

前往app查看评论内容

#Taltz#

头对头牛皮癣研究中，礼来的IL-17A单抗Taltz与强生的IL-23单抗Tremfya相比可提高皮肤清除率

2020-09-03

hjwang88 (审核中...)

前往app查看评论内容

#Taltz#

礼来的IL-17A单抗Taltz治疗非放射性轴向脊柱关节炎，III期临床试验大获成功

2019-09-08

hjwang88 (审核中...)

前往app查看评论内容

#Taltz#

Lilly将启动IXORA-R头对头试验：比较IL-17A单抗Taltz和IL-23单抗Tremfya治疗中度至重度斑块型银屑病患者的疗效

2018-11-21

hjwang88 (审核中...)

前往app查看评论内容

#Taltz#

礼来公司对银屑病关节炎的Taltz在欧盟获批

2018-04-30

hjwang88 (审核中...)

前往app查看评论内容

#Taltz#

LANCET：牛皮癣患者福音！新药Taltz赶走可怕的牛皮癣并发症

2017-12-10

hjwang88 (审核中...)

前往app查看评论内容

#Taltz#

FDA批准银屑病治疗药Taltz

2016-11-21

科室
- - 订阅+
  - 更多科室
工具
服务